

FDA APPROVED TREATMENTS FOR GYNECOLOGICAL CANCERS

CANCER OF THE OVARY:

DATE	DRUG	INDICATION
Dec. 1978	Platinol (cisplatin)	Metastatic ovarian tumors - in established combination therapy with other approved chemotherapeutic agents: Ovarian-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Platinol and Adriamycin. Platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Platinol therapy.
June 1980	Alkeran (melphalan)	palliation of non-resectable epithelial carcinoma of the ovary
Dec. 1987	Adriamycin PFS (doxorubicin HCl)	used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types
March 1989	Paraplatin (carboplatin)	Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Dec. 1990	Hexalen (altretamine)	Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.
July 1991	Paraplatin (carboplatin)	Initial chemotherapy of advanced ovarian carcinoma in combination with other approved chemotherapeutic agents.
Dec. 1992	Taxol (paclitaxel)	Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy.
June 1994	Taxol (paclitaxel)	New dosing regimen for patients who have failed initial or subsequent chemotherapy for metastatic carcinoma of the ovary
May 1996	Hycamtin (topotecan)	Treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy.

April 1998	Taxol (paclitaxel)	For first-line therapy for the treatment of advanced carcinoma of the ovary in combination with cisplatin.
June 1999	Doxil (doxorubicin liposomal)	Accel. Approv. (clinical benefit not established) Treatment of metastatic carcinoma of the ovary in patient with disease that is refractory to both paclitaxel and platinum based regimens. *Recently converted to full approval.
June 2000	Taxol (paclitaxel)	First line ovarian cancer with 3 hour infusion.